Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating the efficacy and safety of Inavolisib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in PIK3CA-mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Inavolisib (Inavolisib)
• Palbociclib (palbociclib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-09